Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]

Sangart (Sa Diego, CA) a clinical-stage biopharmaceutical focused on perfusion of ischemic tissue and targeted oxygen delivery in the capillaries, closed a $50M Series G financing. Participants include Leucadia.

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

Sangart (San Diego, CA) a clinical-stage artificial blood substitute focused on targeting oxygen delivery to tissues that are insufficiently oxygenated, closed a $50M Series F financing, the final tranche of the $100M round. Participants include Leucadia National who owns approximately 92% of the company after investing approximately $146.2M since 2003.

  

to top of page...